AMT-676 in Patients With Advanced Solid Tumors - Trial NCT06400485
Access comprehensive clinical trial information for NCT06400485 through Pure Global AI's free database. This Phase 1 trial is sponsored by Multitude Therapeutics Inc. and is currently Not yet recruiting. The study focuses on Advanced Solid Tumors. Target enrollment is 24 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Multitude Therapeutics Inc.
Timeline & Enrollment
Phase 1
May 09, 2024
Feb 14, 2026
Primary Outcome
Recommended Phase 2 Dose (RP2D),Maximum Tolerated Dose (MTD),Type, incidence and severity of Adverse Events
Summary
This is a first-in-human, non-randomized, open-label, multicenter Phase 1 study will evaluate
 the Maximum tolerated dose (MTD)/the recommended Phase 2 Dose (RP2D), safety, tolerability,
 anti-drug activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-676 in
 Patients with Advanced Solid Tumors.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06400485
Non-Device Trial